Nair et al., 1996 - Google Patents
Cells treated with TAP-2 antisense oligonucleotides are potent antigen-presenting cells in vitro and in vivo.Nair et al., 1996
- Document ID
- 4789228240418977385
- Author
- Nair S
- Snyder D
- Gilboa E
- Publication year
- Publication venue
- Journal of immunology (Baltimore, Md.: 1950)
External Links
Snippet
Abstract Treatment of RMA and EL4 cells or freshly isolated splenocytes with antisense (AS) oligonucleotides directed against the TAP-2 gene recreates the phenotype seen in cells that are genetically deficient in TAP function. Cells incubated with AS oligonucleotides exhibit …
- 210000004027 cells 0 title abstract description 288
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
- C12N5/0602—Vertebrate cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7012788B2 (en) | Antigen-specific T cell receptors and T cell epitopes | |
| US8486693B2 (en) | Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods | |
| Banchereau et al. | Dendritic cells as therapeutic vaccines against cancer | |
| Shrikant et al. | CTLA-4 Blockade Reverses CD8+ T Cell Tolerance to Tumor by a CD4+ T Cell–and IL-2-Dependent Mechanism | |
| US7378087B2 (en) | Method of enhancing an immune response | |
| JP6676759B2 (en) | New generation of antigen-specific TCR | |
| Hamilton et al. | Immunological targeting of tumor cells undergoing an epithelial-mesenchymal transition via a recombinant brachyury-yeast vaccine | |
| Degl'Innocenti et al. | Peripheral T cell tolerance occurs early during spontaneous prostate cancer development and can be rescued by dendritic cell immunization | |
| JP2024041873A (en) | Composition and method for producing t-cell | |
| EP2069381B1 (en) | Agents and methods to elicit anti-tumor immune response | |
| Wennhold et al. | CD40-activated B cells induce anti-tumor immunity in vivo | |
| US5831068A (en) | Method to increase the density of antigen on antigen presenting cells | |
| Liechtenstein et al. | Anti-melanoma vaccines engineered to simultaneously modulate cytokine priming and silence PD-L1 characterized using ex vivo myeloid-derived suppressor cells as a readout of therapeutic efficacy | |
| PT2201100E (en) | Enhancing the t-cells stimulatory capacity of human antigen presenting cells and their use in vaccination | |
| CN103570818B (en) | Tumor antigenic polypeptide and the purposes as tumor vaccine thereof | |
| Liu et al. | TAP peptide transporter-independent presentation of heat-killed Sendai virus antigen on MHC class I molecules by splenic antigen-presenting cells. | |
| Keller et al. | Innate signaling regulates cross‐priming at the level of DC licensing and not antigen presentation | |
| Nair et al. | Cells treated with TAP-2 antisense oligonucleotides are potent antigen-presenting cells in vitro and in vivo. | |
| CN108607094A (en) | The T cell vaccine and its preparation method and application constructed by secretory body by genetically engineered artificial antigen's presenting cells | |
| Palmowski et al. | The use of HLA class I tetramers to design a vaccination strategy for melanoma patients | |
| US20070196335A1 (en) | Immune Modulation By Regulating Expression Of The "Minor" Gene In Immune Dendritic Cells | |
| Nimmerjahn et al. | Efficient generation and expansion of antigen‐specific CD4+ T cells by recombinant influenza viruses | |
| WO2004031380A1 (en) | Method of strengthening foreign epitope presentation by mhc class i by inhibiting tap activity | |
| Faiola et al. | Influence of CD4 T cells and the source of major histocompatibility complex class II‐restricted peptides on cytotoxic T‐cell priming by dendritic cells | |
| CA2559840A1 (en) | Prostatic acid phosphatase antigens |